Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
We enrolled 18 male adults with high-functioning autism and 20 typically developed (TD) male subjects
Research involving incretin-based therapies has shown reductions in: waist circumference, visceral fat, liver fat, and total body fat percentage
We have reached the point of diminishing returns of the proverbial GLP1 trick pony
GLP-1 (Semaglutide): Reduces appetite Slows gastric emptying Increases satiety Supports sustainable calorie reduction Average weight loss: Up to 15% in 68 weeks (NEJM 2021) GLP-1 + GIP (Tirzepatide): GLP-1 + GIP synergy boosts insulin sensitivity Enhances metabolic balance Further suppresses appetite and cravings Average weight loss: Up to 21% in 72 weeks (SURMOUNT-1) Compounded vs
